Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Persistent Obesity Post-Bariatric Surgery (GRABS)
NCT06162715Phase 3Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in obesity comparing Tirzepatide Group with Control - Standard of care Post-Gastric Bypass Surgery (2 arms). Primary endpoints: Weight loss at 24 weeks and Gastrointestinal symptoms at 24 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06162715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162715.